Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
plasma cell neoplasms
MeSH D054219 - plasma cell neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009370:
Neoplasms by histologic type
0 Companies
0 Drugs
Success rate
D054219:
Plasma cell neoplasms
1 Company
1 Drug
$
Success rate
D000075363:
Immunoglobulin light-chain amyloidosis
0 Companies
0 Drugs
Success rate
D008258:
Waldenstrom macroglobulinemia
24 Companies
5 Drugs
$
Success rate
D009101:
Multiple myeloma
80 Companies
34 Drugs
$
Success rate
D010954:
Plasmacytoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
77
%
71/92
Phase 2
27
%
32/117
Phase 3
9
%
5/56
Approved:
1
Overall Success rate:
2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bristol Myers Squibb
Idecabtagene vicleucel
,
Sodium lactate
,
Microcrystalline cellulose
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use